Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Shares Outstanding (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Shares Outstanding for 11 consecutive years, with $116.3 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 14.0% to $116.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $116.3 million through Dec 2025, up 14.0% year-over-year, with the annual reading at $116.3 million for FY2025, 14.0% up from the prior year.
  • Shares Outstanding for Q4 2025 was $116.3 million at Intellia Therapeutics, roughly flat from $115.8 million in the prior quarter.
  • The five-year high for Shares Outstanding was $116.3 million in Q4 2025, with the low at $69631.0 in Q3 2023.
  • Average Shares Outstanding over 5 years is $75.7 million, with a median of $81.8 million recorded in 2022.
  • The sharpest move saw Shares Outstanding surged 34.16% in 2021, then increased 3.02% in 2022.
  • Over 5 years, Shares Outstanding stood at $74.5 million in 2021, then rose by 16.94% to $87.1 million in 2022, then grew by 6.77% to $93.0 million in 2023, then grew by 9.71% to $102.0 million in 2024, then rose by 14.0% to $116.3 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $116.3 million, $115.8 million, and $105.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.